Whether they sold following the November 9, 2026 disclosure or continue to hold their shares, Zura Bio shareholders who suffered losses after the Company announced that its Phase 2 TibuSHIELD trial failed to meet its primary endpoint may be eligible to seek recovery.
NEW YORK, Nov. 10, 2026 /PRNewswire/ -- Investors who lost money on Zura Bio Limited (NASDAQ: ZURA) following the Company's disclosure that its Phase 2 TibuSHIELD trial of tibulizumab failed to meet its Week 16 primary endpoint at either dose tested may be eligible to seek recovery. Selling does not end that right, and shareholders who exited into the drop and those still holding ZURA may both be eligible. If you lost money on ZURA, you are encouraged to find out whether your losses qualify for recovery today. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com or by telephone at (888) SueWallSt.
TibuSHIELD had enrolled 247 participants. Tibulizumab failed to meet the primary endpoint at either dose tested. That endpoint measured the percentage change from baseline in total abscess and inflammatory nodule count at Week 16. Key secondary endpoints, including HiSCR50 and HiSCR75, were also not met. Following these results, Zura Bio discontinued development of tibulizumab for hidradenitis suppurativa.
SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of ZURA investors who suffered losses. Eligibility turns on when shares were bought and the losses documented, not on whether the shares are still in your account.
If you bought ZURA shares and are now holding a loss, request a no-cost review of your ZURA losses or call (888) SueWallSt.
WHY SUEWALLST : SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured billions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
Frequently Asked Questions About the ZURA Investigation
Q: How much did ZURA stock drop? A: Shares fell fell approximately 72% at the market open on November 9, 2026 after the Company disclosed that its Phase 2 TibuSHIELD trial of tibulizumab did not meet its Week 16 primary endpoint at either dose tested and that it was discontinuing development in hidradenitis suppurativa. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.
Q: Who is eligible to participate in the ZURA investigation? A: Investors who purchased ZURA stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: When did Zura Bio allegedly mislead investors? A: The investigation concerns statements made before the corrective disclosure that allegedly caused investors to purchase securities at inflated prices.
Q: What do ZURA investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery . No immediate action is required to remain eligible to participate in the investigation.
Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my ZURA shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought ZURA and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.
Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
Tel: (888) SueWallSt
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
View original content to download multimedia:https://www.prnewswire.com/news-releases/zura-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-zura-bio-limited-302934820.html
SOURCE SueWallSt.com
